In fact, one candidate identified in this analysis as a potential RIDD substrate is the ER-resident FC receptor Like A (Fcrla), which has been previously identified as part of a BATF3/IRF8 transcriptional program that confers tumor immunogenicity in cDC1s independently of cross-presentation (52). This evidence concerns the gene FCRLA and neoplasm.